TheFlyOnTheWall.com reported this morning that Gilead Sciences, Inc. (NASDAQ:GILD), announced that the company has submitted a New Drug Application to Japan’s Pharmaceutical and Medical Devices Agency for approval of sofosbuvir, which is a nucleotide analog polymerase inhibitor for the treatment of chronic hepatitis C virus infection. Gilead Sciences, Inc.(NASDAQ:GILD) opened trading today at $82.18 and…
Stock Alert: Facebook Inc (NASDAQ:FB) Officially Launches Slingshot Photo App
Facebook Inc (NASDAQ:FB) announced on their blog today “We’re excited to introduce the second app from Facebook Creative Labs: Slingshot. Slingshot lets you quickly share everyday moments with lots of people at once.”
Google Shopping Stop Working
Google’s (GOOG)’s new service has been stopped because of the access demand.
Potbelly Corporation More Palatable Valuation
Potbelly’s stock has declined nearly 30% so far this year and is down more than 40% since late October. While estimates have retracted about 10% on weather-related softness in the first quarter and the company’s decision to enter a new hub market in 2014, the bulk of the stock decline is the result of multiple…
Eagle Pharmaceuticals’ Ryanodex Receives Patent for Treatment of Exertional Heat Stroke
Eagle Pharmaceuticals announced today that its dantrolene sodium injectable suspension (brand name Ryanodex) has received a patent for the treatment of exertional heat stroke, which will provide coverage through 2023. Patent ‘460 brings the company’s IP surrounding Ryanodex to four issued patents. As the patent coverage surrounding the company’s best-in-class formulation solidifies, Eagle will initiate…
McGraw Hill Investor Day Reinforces Positive Long-Term Outlook
McGraw Hill Financial hosted its inaugural investor day in New York on Tuesday, March 18. The headlines were that the company: 1) reaffirmed its 2014 guidance (not really a surprise given that it just issued guidance last month); 2) announced that it is evaluating strategic alternatives for McGraw Hill Construction; 3) announced a three-year target…
Idera Pharmaceuticals presented preclinical evidence
Idera Pharmaceuticals presented preclinical evidence
Smart Data has been acquired by Xerox
Smart Data has been acquired by Xerox.
Main Street Capital Seold 4 million shares
Main Street Capital Seold 4 million shares
Canaccord Genuity Reported Buy Recommendation For Castlight Health.
Canaccord Genuity Reported Buy Recommendation For Castlight Health.
- 1
- 2